The Background and Future of Quizartinib for AML

Video

Mark J. Levis, MD, PhD, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

Clinical Pearls

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

  • Quizartinib could play a crucial role in the treatment of FLT3-ITD acute myeloid leukemia
  • Quizartinib has produced many clinically meaningful responses
  • The phase IIb study will analyze 30 mg and 60 mg doses
Related Videos
A panel of 3 experts on GVHD
A panel of 3 experts on GVHD
Related Content
Improving Identification Within Asian American Subgroups With Ovarian Cancer

Improving Identification Within Asian American Subgroups With Ovarian Cancer

April 12th 2024
Article

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

April 11th 2024
Article

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

Read More

Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

May 17th 2022
Podcast

In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.

Listen

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

April 10th 2024
Article

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Read More

Targeting Multiple Myeloma With the Latest Therapies

Targeting Multiple Myeloma With the Latest Therapies

April 9th 2024
Article

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Read More